Skip to main content

Table 4 Multivariate analysis: overall survival and local-regional progression-free survival

From: Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Variable OS LRPFS
  p HR 95% CI p HR 95% CI
Gender (Female vs. Male) 0.288 0.802 0.534-1.205 0.278 0.753 0.450-1.258
Age (years) (≥65 vs. <65) 0.297 0.817 0.558-1.195 0.248 0.760 0.477-1.211
Pathological type (Non-squamous vs. Squamous) 0.106 1.364 0.936-1.988 0.494 1.184 0.729-1.924
T stage (T3-T4 vs. T1-T2) 0.728 1.067 0.740-1.540 0.702 1.097 0.684-1.759
Distant metastatic lesions (No radiotherapy vs. Radiotherapy) 0.682 1.083 0.740-1.584 0.652 1.118 0.689-1.812
Intrathoracic primary tumors (No response vs. Response) 0.592 1.124 0.733-1.724 0.581 1.188 0.644-2.190
GTV (<175 cm3 vs. ≥175 cm3) 0.008 1.747 1.153-2.646 0.003 2.321 1.336-4.032
Post-treatment KPS (Decreased ≥10 vs. Stable or increased ≥10) 0.000 6.282 3.568-11.058 0.000 8.038 3.769-17.140
N stage (N2-N3vs. N0-N1) 0.059 1.636 0.981-2.727 0.234 1.438 0.790-2.615
Chemotherapy cycles (2–3 vs. 4–5) 0.035 1.484 1.028-2.144 0.128 1.431 0.903-2.268
Intrathoracic primary tumors radiation doses (<63Gy vs. ≥63Gy) 0.057 1.433 0.989-2.075 0.051 1.562 0.999-2.443
\